Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1586/17446651.2014.926810 http://scihub22266oqcxt.onion/10.1586/17446651.2014.926810 25264451!4162655!25264451     free     free     free       Expert+Rev+Endocrinol+Metab 2014 ; 9 (4): 397-409 Nephropedia Template TP {{tp|p=25264451|t=2014. Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis |pdf=|usr=}}{{25264451}} gab.com Text Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis JO: Expert Rev Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=25264451 #FOAvip Aromatase excess syndrome is characterized by pre- or peripubertal onset of gynecomastia due to estrogen excess because of a gain-of-function mutation in the aromatase gene (CYP19A1). Subchromosomal recombination events including duplication, deletion, and inversion has been identified. The latter two recombinations recruit novel promoters for CYP19A1 through a unique mechanism. Gynecomastia continues for life, and although the general condition is well preserved, it may cause psychological issues. Minor symptoms (variably advanced bone age and short adult height), if present, are exclusively because of estrogen excess. Serum estradiol levels are elevated in 48% of affected males, but are not necessarily useful for diagnosis. Molecular analysis of CYP19A1 mutations is mandatory to confirm aromatase excess syndrome diagnosis. Furthermore, the use of an aromatase inhibitor can ameliorate gynecomastia. Twit Text FOAVip Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis ????Expert Rev Endocrinol Metab http://www.kidney.de/pget.php?&tw=1&pmid=25264451 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25264451 #FOAvip English Wikipedia <ref>{{Cite pmid|25264451}}</ref> Understanding the pathological manifestations of aromatase excess syndrome: lessons for clinical diagnosis #MMPMID25264451 Shozu M; Fukami M; Ogata T Expert Rev Endocrinol Metab 2014[Jul]; 9 (4): 397-409 PMID25264451show ga Aromatase excess syndrome is characterized by pre- or peripubertal onset of gynecomastia due to estrogen excess because of a gain-of-function mutation in the aromatase gene (CYP19A1). Subchromosomal recombination events including duplication, deletion, and inversion has been identified. The latter two recombinations recruit novel promoters for CYP19A1 through a unique mechanism. Gynecomastia continues for life, and although the general condition is well preserved, it may cause psychological issues. Minor symptoms (variably advanced bone age and short adult height), if present, are exclusively because of estrogen excess. Serum estradiol levels are elevated in 48% of affected males, but are not necessarily useful for diagnosis. Molecular analysis of CYP19A1 mutations is mandatory to confirm aromatase excess syndrome diagnosis. Furthermore, the use of an aromatase inhibitor can ameliorate gynecomastia. ?Understanding the pathological manifestations of aromatase excess synd(epmc).pdf DeepDyve Pubget Overpricing